Literature DB >> 29079868

[New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation].

T Henze1, W Feneberg2, P Flachenecker3, D Seidel4, H Albrecht5, M Starck2, S G Meuth6.   

Abstract

The symptomatic treatment of multiple sclerosis (MS) is nowadays of similar importance as immunotherapy within a comprehensive treatment concept of this chronic disease. It makes a considerable contribution to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of the quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Clinical Competence Network Multiple Sclerosis ("Klinisches Kompetenznetz Multiple Sklerose", KKN-MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation have taken place. These new findings together with further aspects of disease measurement methods and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in several individual contributions. In this article the symptoms of cognitive disorders and the growing impact of rehabilitation are discussed.

Entities:  

Keywords:  Cognitive disorders; Multiple sclerosis; Rehabilitation; Review; Symptomatic treatment

Mesh:

Year:  2018        PMID: 29079868     DOI: 10.1007/s00115-017-0443-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  31 in total

1.  Prognostic factors in multidisciplinary rehabilitation treatment in multiple sclerosis: an outcome study.

Authors:  M G Grasso; E Troisi; F Rizzi; D Morelli; S Paolucci
Journal:  Mult Scler       Date:  2005-12       Impact factor: 6.312

Review 2.  Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature.

Authors:  Amanda R O'Brien; Nancy Chiaravalloti; Yael Goverover; John Deluca
Journal:  Arch Phys Med Rehabil       Date:  2008-04       Impact factor: 3.966

3.  Prospective study of neurorehabilitation in multiple sclerosis.

Authors:  D Kidd; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

4.  Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and performance of everyday life tasks: Actual Reality.

Authors:  Yael Goverover; Nancy Chiaravalloti; John DeLuca
Journal:  Mult Scler       Date:  2015-07-10       Impact factor: 6.312

5.  Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis.

Authors:  A Brenk; K Laun; C G Haase
Journal:  Eur Neurol       Date:  2008-09-27       Impact factor: 1.710

6.  Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis.

Authors:  C M Wiles; R G Newcombe; K J Fuller; S Shaw; J Furnival-Doran; T P Pickersgill; A Morgan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

7.  Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

Authors:  J A Freeman; D W Langdon; J C Hobart; A J Thompson
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

8.  Physical rehabilitation has a positive effect on disability in multiple sclerosis patients.

Authors:  A Solari; G Filippini; P Gasco; L Colla; A Salmaggi; L La Mantia; M Farinotti; M Eoli; L Mendozzi
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

9.  Impact of aerobic training on fitness and quality of life in multiple sclerosis.

Authors:  J H Petajan; E Gappmaier; A T White; M K Spencer; L Mino; R W Hicks
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422

Review 10.  Multidisciplinary rehabilitation for adults with multiple sclerosis.

Authors:  F Khan; L Turner-Stokes; L Ng; T Kilpatrick
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.